[go: up one dir, main page]

EP2197434A4 - Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique - Google Patents

Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique

Info

Publication number
EP2197434A4
EP2197434A4 EP08831905A EP08831905A EP2197434A4 EP 2197434 A4 EP2197434 A4 EP 2197434A4 EP 08831905 A EP08831905 A EP 08831905A EP 08831905 A EP08831905 A EP 08831905A EP 2197434 A4 EP2197434 A4 EP 2197434A4
Authority
EP
European Patent Office
Prior art keywords
modulating
activity
concentration
gene product
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08831905A
Other languages
German (de)
English (en)
Other versions
EP2197434A1 (fr
Inventor
William F Sardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resveratrol Partners LLC
Original Assignee
Resveratrol Partners LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resveratrol Partners LLC filed Critical Resveratrol Partners LLC
Publication of EP2197434A1 publication Critical patent/EP2197434A1/fr
Publication of EP2197434A4 publication Critical patent/EP2197434A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08831905A 2007-09-20 2008-09-17 Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique Withdrawn EP2197434A4 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US97381707P 2007-09-20 2007-09-20
US2322708P 2008-01-24 2008-01-24
US2323408P 2008-01-24 2008-01-24
US2323008P 2008-01-24 2008-01-24
US4876908P 2008-04-29 2008-04-29
US4875608P 2008-04-29 2008-04-29
US4874708P 2008-04-29 2008-04-29
PCT/US2008/076707 WO2009039195A1 (fr) 2007-09-20 2008-09-17 Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique

Publications (2)

Publication Number Publication Date
EP2197434A1 EP2197434A1 (fr) 2010-06-23
EP2197434A4 true EP2197434A4 (fr) 2011-08-10

Family

ID=40468316

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08831905A Withdrawn EP2197434A4 (fr) 2007-09-20 2008-09-17 Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique

Country Status (4)

Country Link
EP (1) EP2197434A4 (fr)
JP (2) JP2010540444A (fr)
CA (1) CA2699908C (fr)
WO (1) WO2009039195A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263051B2 (en) * 2007-08-09 2012-09-11 Hallstar Innovations Corp. Photostabilization of resveratrol with alkoxycrylene compounds
JP5979810B2 (ja) * 2009-10-09 2016-08-31 株式会社山田養蜂場本社 抗老化剤
CA2792993A1 (fr) * 2010-01-21 2011-07-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Composition particuliere pour son application comme medicament
US20120058088A1 (en) * 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP5608629B2 (ja) * 2011-11-28 2014-10-15 アピオン・ジャパン有限会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
EP2895861A4 (fr) * 2012-09-12 2016-06-22 Berg Llc Utilisation de marqueurs dans l'identification d'agents cardiotoxiques et dans le diagnostic et la surveillance d'une myocardiopathie et d'une maladie cardiovasculaire
CN102908338B (zh) * 2012-11-20 2014-05-14 晨光生物科技集团天津有限公司 白藜芦醇微胶囊的制备方法
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
JP5933633B2 (ja) * 2014-06-18 2016-06-15 アピオン・ジャパン有限会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
EP3237295B1 (fr) * 2014-12-23 2023-03-01 Intelligent Packaging Pty Ltd. Procédé de fabrication d'un contenant pour un produit de consommation, revêtu d'une couche contenant du resvératrol
WO2017096049A1 (fr) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Substances pour l'amélioration de la cathépsine b et méthodes d'utilisation
JP6272946B2 (ja) * 2016-05-20 2018-01-31 株式会社山田養蜂場本社 抗老化剤
KR102712656B1 (ko) 2017-01-23 2024-10-04 리제너론 파마슈티칼스 인코포레이티드 Hsd17b13 변종 및 이것의 용도
US11479802B2 (en) 2017-04-11 2022-10-25 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
JP6411624B2 (ja) * 2017-12-26 2018-10-24 株式会社山田養蜂場本社 抗老化剤
BR112020018758A2 (pt) 2018-03-21 2021-01-26 Regeneron Pharmaceuticals, Inc. agente de ácido ribonucleico de fita dupla, célula, vetor, composição farmacêutica, e, métodos para inibição da expressão de 17¿-hidroxiesteroide desidrogenases tipo 13, para tratamento de um indivíduo, para prevenção de um sintoma em um indivíduo, para redução do risco de desenvolver doença hepática crônica, para inibição da progressão de esteatose, para inibição do acúmulo de gotículas de lipídios

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006298876A (ja) * 2005-04-25 2006-11-02 Saisentan Igaku Kenkyusho:Kk サーチュインの活性化剤を含む各種眼疾患治療用組成物
EP1633208A1 (fr) * 2003-05-27 2006-03-15 DSM IP Assets B.V. Nouvelles compositions nutraceutiques et utilisations
AU2004253579B2 (en) * 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
CN1956733B (zh) * 2004-04-07 2012-10-10 白藜芦醇合伙人有限责任公司 营养补充剂及其加工方法
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
AU2006278504B2 (en) * 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same

Also Published As

Publication number Publication date
JP2014058574A (ja) 2014-04-03
WO2009039195A1 (fr) 2009-03-26
EP2197434A1 (fr) 2010-06-23
CA2699908A1 (fr) 2009-03-26
JP2010540444A (ja) 2010-12-24
CA2699908C (fr) 2012-09-11

Similar Documents

Publication Publication Date Title
EP2197434A4 (fr) Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique
EP2151438A4 (fr) Produit pharmaceutique contenant un agoniste de ppar
EP2207539A4 (fr) Compositions désinfectantes pour la peau ou pour des surfaces, contenant des substances d'origine végétale
EP2190439A4 (fr) Synthèse d'oseltamivir contenant des congénères de phosphonate ayant une activité anti-grippale
EP2100610A4 (fr) Composition pharmaceutique contenant de l'hydroxypropylcellulose faiblement substituée
EP2055308A4 (fr) Produit pharmaceutique servant à favoriser la régénération fonctionnelle d'un tissu endommagé
EP2200573A4 (fr) Composés de férulate de resvératrol, compositions contenant lesdits composés et leurs procédés d'utilisation
FR2904294B1 (fr) Tete de distribution de produit fluide.
EP1962827A4 (fr) Compositions pharmaceutiques contenant des combinaisons d'inhibiteurs de la dipeptidylpeptidase 4 avec de la métformine
FR2913341B1 (fr) Dispositif d'ejection jetable d'un produit liquide ou pateux
EP2018872A4 (fr) Produit pharmaceutique
EP2164978A4 (fr) Compositions et procédés pour moduler l'activité d'adamts13
FR14C0020I1 (fr) Compositions pharmaceutiques contenant du fentanyl pour application nasale
EP2637674A4 (fr) Composés contenant du bismuth pour moduler les propriétés d'agents biologiquement actifs
EP2213296A4 (fr) Composition médicinale contenant une protéine chimère extrêmement fonctionnalisée
EP2354224A4 (fr) Nouvelle protéine ayant une activité de fructosyl-valyl-histidine oxydase et produit modifié de celle-ci et utilisation de la protéine ou du produit modifié
EP2138489A4 (fr) Nouveau composé de pyrimidine ayant une structure de benzyl(hétérocycliqueméthyl)amine et produit pharmaceutique la contenant
MA28078A1 (fr) Produits pharmaceutiques contenant des bisphosphonates
EP2089354A4 (fr) Dérivés de naphthalényloxypropényle ayant une activité inhibitrice envers l'histone désacétylase et une composition pharmaceutique contenant ceux-ci
EP1970753A4 (fr) Produit d'identification
EP2307056A4 (fr) Compositions pharmaceutiques aqueuses stables contenant du paracetamol
FR2878835B1 (fr) Ensemble de distribution de produit fluide
EP2484349A4 (fr) Inhibiteur de l'activité héparanase, agent améliorant les rides le contenant, et composition pharmaceutique
EP2285215A4 (fr) Nouveaux composés, compositions pharmaceutiques contenant ceux-ci, et procédés d'utilisation de ceux-ci
FR2892276B1 (fr) Distributeur applicateur d'un produit, typiquement un produit cosmetique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110708

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7056 20060101ALI20110704BHEP

Ipc: A61K 31/05 20060101AFI20110704BHEP

17Q First examination report despatched

Effective date: 20130715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150401